The 3rd Retinal Imaging Biomarkers & Endpoints Summit will bring together leading experts spanning medical directors, researchers, clinical, and imaging scientists from more than 30 organizations spearheading ophthalmic development with deep learning systems and sophisticated AI imaging technologies. It’s here they will explore the latest advancements in retinal imaging, biomarkers, and endpoints for ophthalmic drug development.
Topics will cover a range of retinal conditions, including dry and wet AMD, GA, GR, and DME, focusing on the identification and validation of biomarkers that are vital for diagnosis, prognosis, and treatment response assessment. This meeting is the perfect bridge for those developing and using novel technologies to ensure the efficacious development of endpoints for regulatory approval.
Attendees will benefit from interactive workshops, panel discussions, and case studies, providing practical insights into the real-world challenges and opportunities in retinal disease research. Plus, with 8+ hours of dedicated networking sessions designed to ensure attendees get to meet everyone in the room, it’s a fantastic opportunity to build valuable connections and strengthen collaboration which will aid in fostering partnerships that will drive the future of retinal imaging and treatment outcomes.
And with sessions being delivered by Alexion, Opus Genetics, Inflammx, Bausch + Lomb, REGENXBIO, and many more you won’t want to miss this!
Whether you’re a researcher, drug developer, clinician or solution provider, the 3rd Retinal Imaging Biomarkers & Endpoints Summit promises to be a pivotal point in the calendar for those involved in the development of therapies for retinal diseases.
Join us to be at the forefront of this rapidly advancing field and contribute to the next wave of innovations in retinal health…
View the event guide for more information: https://ter.li/hcmzr0
Secure your pass: https://ter.li/tq8jmz